##  [New extension study data with Novartis drug Gilenya shows patients successfully treated for up to 7 years in relapsing MS ](/us-en/news/media-releases/new-extension-study-data-novartis-drug-gilenya-shows-patients-successfully-treated-7-years-relapsing-ms-0 "New extension study data with Novartis drug Gilenya shows patients successfully treated for up to 7 years in relapsing MS ") 

  Apr 24, 2012